Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05670743 · ClinicalTrials.gov registry record · Phase 2
Pharmacokinetics of Advantage Arrest in Healthy Children 13-Months to 13-Years of Age
A Phase 2 study of Dental Caries in Children, sponsored by Advantage Silver Dental Arrest.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
- 1
- Study location
NCT05670743: Completed Phase 2 study of Dental Caries in Children, sponsored by Advantage Silver Dental Arrest.
NCT05670743 is a Phase 2 study of Dental Caries in Children that has completed, run by Advantage Silver Dental Arrest. The registered enrollment target is 23 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05670743, a Phase 2 study of Dental Caries in Children, has completed, sponsored by Advantage Silver Dental Arrest.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to further characterize basic pharmacokinetic (PK) parameters in healthy children to contribute to evidence for the safety of silver diamine fluoride (SDF; Advantage Arrest). Children with at least one active cavity will be treated and then have blood draws at random time points afterwards.
Primary Outcome
Maximum serum concentration of fluoride
Conditions Studied
Interventions
- DRUG 38% silver diamine fluoride
Study Locations (1)
Washington
- Center for Pediatric Dentistry - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2023-03-01 |
| Est. Completion | 2024-08-01 |
| Phase | Phase 2 |
What the finished NCT05670743 record still lists
NCT05670743 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Dental Caries in Children appearing as the primary indexed condition, and to 1 intervention - of which 38% silver diamine fluoride is the first listed.
NCT05670743 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT05670743 about?
NCT05670743 is a clinical study titled "Pharmacokinetics of Advantage Arrest in Healthy Children 13-Months to 13-Years of Age". The purpose of this study is to further characterize basic pharmacokinetic (PK) parameters in healthy children to contribute to evidence for the safety of silver diamine fluoride (SDF; Advantage Arrest). Children with at least one active cavity will be treated and then have blood draws at random tim...
What is the current status of trial NCT05670743?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2023-03-01. Estimated completion is 2024-08-01.
What conditions does trial NCT05670743 study?
This clinical trial studies the following conditions: Dental Caries in Children.
What interventions are being tested in trial NCT05670743?
The interventions under investigation include: 38% silver diamine fluoride (DRUG).
Who is sponsoring clinical trial NCT05670743?
This trial is sponsored by Advantage Silver Dental Arrest, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05670743 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dental Caries in Children
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05670743's enrollment target sits among peer trials
23 1784th of 2000 higher than 211 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI